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Despite some expression of folate receptor  in human
mesothelioma cells, internalization of methotrexate is
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Objective: As a response to a published report documenting some expression of
folate receptor  in human mesothelioma, studies were carried out examining the
role of this receptor versus that of the reduced folate carrier in the internalization of
folate analogs in this neoplasm.
Methods: Influx measurements of tritiated methotrexate were carried out in 4
mesothelioma cell lines, and 2 additional cell lines were used as comparators.
Relative gene-expression analysis for the carrier and receptor gene was done by
using real-time reverse transcriptase–polymerase chain reaction in the above-men-
tioned cell lines and mesothelioma tumor tissues obtained from patients.
Results: Internalization of tritiated methotrexate in mesothelioma cell lines grown at
physiologic folate levels was carrier mediated rather than receptor mediated. Influx
of this model permeant by these cells exhibited characteristics of carrier-mediated
membrane transport and was only minimally reduced by the addition of 5 mol/L
folic acid, a concentration of this natural folate that would have completely inhibited
influx by the folate receptor. Gene-expression analysis revealed prominent expres-
sion of the folate receptor in some but not all mesothelioma cell lines, and in only
one case was expression of this receptor gene greater than expression of the reduced
folate carrier gene. Similar analysis of human mesothelioma tumor tissue showed
that, with few exceptions, receptor gene expression was substantially less than that
for the carrier gene.
Conclusion: In view of the ongoing reduced folate carrier-mediated internalization
that occurs in mesothelioma cells, these results would seem to argue against a role
for the folate receptor in the internalization and cellular pharmacokinetics of
methotrexate and other classic folate analogs in this neoplasm. Identifying the
mediated route for internalization of these agents in tumor cells is a prerequisite for
improving their structural design.
Folate compounds, including folate analogs, are internalized by mam-malian cells through either carrier-mediated1-3 or receptor-mediated4,5processes. The former uses binding to a mobile carrier at the plasmamembrane surface and mediates bidirectional flux. The latter usesmuch higher affinity binding at the membrane surface to a receptorprotein that more slowly mediates unidirectional flux after internal-
ization of the receptor-folate compound complex in the manner of many other
receptor-ligand processes.6,7 The extent to which receptor-mediated processes con-
tribute to net internalization of folates and their analogs in tumor cells remains
controversial4 but will depend on the level of expression of the corresponding gene
vis-a`-vis the reduced folate carrier gene (RFC1) in any specific cell type. Translo-
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cation through the plasma membrane of folate analogs by
the RFC1 carrier-mediated process is what is commonly
found in tumor cells.1-3 Because this process is much more
efficient5,8 than receptor-mediated translocation, the relative
level of expression required for the latter to contribute
significantly to net intracellular accumulation in tumor cells
is proportionally greater, particularly in the case of folate
analogs. Net intracellular accumulation of folate com-
pounds in tumor cells also reflects the operation of one or
more members of the canalicular multiorganic anion trans-
porter (cMOAT/MRP) family of adenosine triphosphata-
ses,9,10 which extrude these compounds through the plasma
membrane. However, this aspect of the cellular pharmaco-
kinetics of folate analogs is outside the focus of the current
presentation.
Folate analogs have shown11-13 interesting clinical activ-
ity against human mesothelioma, a neoplasm found, for the
most part, to be relatively unresponsive to most cytotoxic
agents.11,12 In view of these clinical findings and other
results14 showing that the folate receptor  gene (FRA) is
expressed in human mesothelioma but not in normal pleural
mesothelium and the suggestion14 that this expression may
be relevant to the responsiveness of this human neoplasm to
folate analogs, it was of interest to determine to what extent
receptor-mediated versus carrier-mediated processes might
actually account for the internalization of these folate ana-
logs in human mesothelioma. We addressed this question at
both the biochemical and the molecular levels. Our results
showed that human mesothelioma cell lines predominantly
internalized a model permeant (tritiated methotrexate) by
means of a carrier-mediated mechanism, ostensibly encoded
by the RFC1 gene, with little, if any, receptor-mediated
internalization. They also showed that expression of the
FRA gene in these cell lines and in patient-derived mesothe-
lioma was almost always substantially less than expression
of the RFC1 gene. These results are presented below.
Materials and Methods
Cell Lines and Transport Measurements
Mesothelioma cell lines were cultured in RPMI medium in accord-
ance with procedures published earlier.15,16 The VAMT-1 and
JMN cell lines were generously provided by Dr B. Gerwin in the
laboratory of Dr Curtis Harris at the National Cancer Institute
(Bethesda, Md). The MESO 9 and MESO 10 cell lines were
generously provided by Dr S. Jhanwar and the SKOV-3 (ovarian
cancer) by Dr D. Spriggs (both at Memorial Sloan-Kettering
Cancer Center, New York, NY). CCRF-CEM (acute lymphoblastic
leukemia) and TSU-PR1 (prostate cancer) cells were obtained
from the American Type Culture Collection and cultured in RPMI
medium, as described earlier.15,16 Measurement of 3H methotrex-
ate influx was carried out by procedures described in detail previ-
ously.1,2,15,16 Before the measurements of influx were carried out,
the cells were grown to late logarithmic phase either in 2.2 mol/L
folic acid or for 2 transfer generations in 20 nmol/L dIL5-formyl
tetrahydrofolate. The cells were resuspended in 0.2 mL of HMO
buffer with 7 mmol/L D-glucose in 1.5-mL Eppendorf tubes, and
transport experiments were carried out by incubating cells with 2
mol/L radioactive folate analog 3H methotrexate at 37°C for
varying time intervals. Parallel experiments were conducted in the
presence and absence of 5 or 100 mol/L folic acid.
Quantitative Reverse Transcriptase–Polymerase Chain
Reaction Analysis
Total RNA was prepared with Trizol reagent (Gibco BRL; Life
Technologies, Rockville, Md) from all the tumor cell lines. First-
strand complementary DNA was prepared by using the Superscript
System (Gibco BRL). Mesothelioma tumor samples were har-
vested from patients at the time of surgical resection and snap-
frozen in liquid nitrogen. Messenger RNA was purified from these
tissue samples by using the Quick Prep mRNA Purification Kit
(Amersham Pharmacia Biotech Inc, Piscataway, NJ) and then
reverse transcribed by using M-MLV RT and random hexamers
(Gibco BRL). RFC1 and FRA gene expression was quantified with
the aid of an ABI Prism 7700 Sequence Detection System (Taq-
Man; PE Biosystems, Foster City, Calif). With the nuclease activ-
ity of Taq Polymerase, this method is based on the displacement
and cleavage of a labeled fluorogenic probe specific to the target
sequence flanked by polymerase chain reaction (PCR) primers.
This allows the quantitation of target genes while PCR is in the log
phase of amplification. A detailed description of this methodology
has been previously provided.17 The primer and probe sets were
designed with Primer Express Software (Applied Biosystems, Foster
City, Calif), and the sequences are as follows: RFC1, forward
5-CCGCGGCTCCTACCAGTT-3, reverse 5-AAGACCAGGG
CACAGAGCTCTT-3, probe 6FAM-ATTCTGAACACCGTCG
CTTGGAAGACACT-TAMRA; FRA, forward 5-GAGCAATGG
TGGGAAGATTGTC-3, reverse 5-CTCCCACTGCGCACTTG
TTA-3, probe 6FAM-AACCCTGAAGTCCAGTTCCAGCCCTT
GT-TAMRA; and -actin, forward 5-CTGGCACCCAGCACAA
TG-3, reverse 5-GCCGATCCACACGGAGTACT-3, probe
6FAM-TCAAGATCATTGCTCCTCCTGAGCGC-TAMRA.
Relative quantitation was done by using the comparative
threshold cycle (CT) method. The CT indicates the fractional cycle
number at which the amplified target reaches a fixed threshold. The
amount of target gene (RFC1 and FRA) normalized to an endo-
genous reference (-actin) is given as follows:
2CT,18-20
where CT is CT for the target gene minus CT for the reference
gene. Serial dilutions of a control cDNA were run in triplicate,
amplifying -actin to generate a standard curve (Figure 1). The
slope of this curve is used for calculating the run efficiency. The
relation is given as follows:
E  101/s  1,
where E is the efficiency and S is the slope. In our hands the
efficiency of all runs was greater than 0.975, with a correlation
coefficient of 0.998 or greater.
Tissues and Clinical Database
Surgical specimens were obtained from consecutive patients un-
dergoing thoracotomy and surgical resection. They were divided
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into small samples (3  3  3 mm), snap-frozen, and stored at
140°C. Histologic sections were reviewed by a pathologist to
identify those tumor samples that had predominantly tumor cells
among nucleated cells on the slide. Relevant clinical data were
collected for all the patients and linked to the specimens, and the
link-up to patient identifiers was destroyed by the Tumor Bank before
distribution to this project to protect patient confidentiality. Tissue
collection and these experiments were performed in accordance
with the guidelines of Memorial Sloan-Kettering Cancer Center.
Materials
Samples of 3H methotrexate were obtained from Moravek Bio-
chemicals, Inc (Brea, Calif). This and all other folate compounds
were purified by means of high-performance liquid chromatogra-
phy to greater than 98% purity.21 All other chemicals were reagent
or molecular biology grade.
Results
The results of experiments measuring the mediated inter-
nalization of 3H methotrexate by 4 human mesothelioma
cell lines are given in Figure 2 and Table 1. The results
obtained with VAMT-1 cells are compared in Figure 1 with
those obtained with CCRF-CEM and SKOV-3 cells. In each
case the time course for internalization obtained with 2
mol/L 3H methotrexate was consistent with that expected
for an RFC1-mediated process.1,2 Internalization was ini-
tially rapid and constant, with time followed by an expo-
nential approach to steady state (influx efflux). Moreover,
the addition of 5 mol/L folic acid to the cell suspension, an
extremely effective inhibitor of FRA-mediated, but not
RFC1-mediated, internalization,1-5 had only a minimal ef-
fect on these time courses. However, influx could be inhib-
ited by a much higher concentration (100 mol/L) of folic
acid, a result consistent with a role for RFC1 in the inter-
nalization of 3H methotrexate in these cells. These results
were similar to those obtained (Figure 2 and Table 1) with
the other mesothelioma cell lines and the CCRF-CEM and
SKOV-3 cell lines, which were used as comparators. Again,
the data in Table 1 show only a slight effect of 5 mol/L
folic acid on influx of 3H methotrexate. The same results
after folic acid addition were obtained when the cells were
grown in 2.2 mol/L folic acid or 20 nmol/L dIL5-formyl
tetrahydrofolate, a concentration approximating the physio-
logic level of folate in human blood. Because FRA has an
extremely high affinity (Km  1  0.2 mmol/L) for this
natural folate, whereas RFC1 has extremely low affinity
(Km  100  20 mol/L), these results clearly implicate
RFC1 as the predominant, if not exclusive, route for medi-
ated internalization of 3H methotrexate in VAMT-1 cells, as
is the case for CCRF-CEM1 and SKOV-3 cells.
As an adjunct to the studies described above, we also
examined, for the purpose of comparison, these human
mesothelioma cell lines, as well as CCRF-CEM and
SKOV-3 cells, for the expression of both FRA and RFC1
genes by using real-time quantitative reverse transcriptase–
PCR (RT-PCR), with -actin as the reference comparator
gene (Figure 3). The data in Figure 4 show that expression
of these genes was extremely variable over a wide range. In
only one case (MESO 10) was expression of FRA equal to
or higher than that of RFC1. Moreover, expression of RFC1
appeared to show (Table 1) a general correlation with influx
of 3H methotrexate in these cells. Influx was lowest in the
case of MESO 9 and MESO 10 and highest in the case of
VAMT-1, the cell lines with the least and greatest expres-
sion of the RFC1 gene, respectively. The single discrepancy
between the rate of internalization and RFC1 gene expres-
Figure 1. Standard curve of CT value against log of starting quantity of -actin. Dots represent standard samples
plotted in triplicate. The slope is 3.37, and the correlation coefficient is 0.998.
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sion occurred with SKOV-3 cells. However, in this case,
and to some extent with the other tumor cell lines, func-
tional expression of the RFC1 gene could also reflect dif-
ferences in the rate of translation of RFC1 mRNA. The
results with SKOV-3 cells, showing that FRA gene expres-
sion was far greater than for RFC1, was of interest given the
finding that 3H methotrexate internalization in these cells
was relatively low and apparently RFC1 mediated. The
level of expression of FRA in SKOV-3 cells was even
higher than that found in all the other tumor cells included
here in a parallel analysis. It is known that high expression
of FRA is a common occurrence in ovarian cancer cells.9
The results obtained with SKOV-3 cells, for which there is
companion transport data (Figure 2), are strikingly consis-
tent with the accepted notion that receptor-mediated inter-
nalization of 3H methotrexate is much less efficient than
carrier-mediated internalization.
The same RT–PCR analysis was carried out (Figure 5)
with a large number of mesothelioma specimens obtained
from patients during surgical resection of tumors. These
data also revealed highly variable expression of both RFC1
and FRA genes. However, with few exceptions, levels of
expression for FRA were very substantially lower than those
for RFC1. The data also show that there were no appreciable
differences observed (Figure 5) in the level of expression of
either gene among tumors with epitheloid or mixed (epithe-
loid-sarcomatoid) histologic features. Only one of the avail-
able samples was pure sarcomatoid in origin and was in-
cluded because RFC1 gene expression in this sample was
exceptionally high compared with expression of FRA.
Discussion
FRA- and carrier-mediated transport of folate compounds in
mammalian cells are readily distinguishable by the avidity
TABLE 1. Internalization of 3H methotrexate by human mesothelioma, CCRF-CEM, SKOV-3, and TSU-PR1 cells in the
presence and absence of 5 mol/L folic acid
Cell type Histopathology
Influx velocity (pmol/min per 107 cells)
Relative RFC1 expressionNo folic acid 5 mol/L folic acid
CCRF-CEM ALL 9.1 2 9.1 1 50
VAMT-1 Mesothelioma 8.8 2 8.4 1 43
JMN Mesothelioma 5.8 1 4.9 1 15
TSU-PR1 Prostate carcinoma 3.7 0.8 3.5 1 7
MESO-10 Mesothelioma 2.6 0.4 2.4 0.3 4
SKOV-3 Ovarian carcinoma 2.5 0.4 2.2 0.3 15
MESO-9 Mesothelioma 2.4 0.5 2.2 0.5 3
One to 2  106 cells/mL grown in physiologic folate were incubated for 1 to 6 minutes at 37°C with 2 mol/L 3H methotrexate in HMO buffer in the presence
and absence of 5 mol/L folic acid. Additional experimental details are given in the text. Data are average of 3 experiments  SEM.
Figure 2. Time course for internalization of 3H methotrexate in various human tumor cells. Cells were incubated
with 2 mol/L 3H methotrexate (MTX) with or without 5 mol/L folic acid in 50 mmol/L HEPES and 180 mmol/L
sucrose brought to pH 7.4 with MgO. Aliquots of cell suspensions were removed at the indicated times for
processing. Additional details are provided in the text. Average of 3 experiments with SEM  20% or less.
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of the receptor- or carrier-permeant interaction.1-5 Binding
of these compounds by FRA occurs with an affinity several
orders of magnitude greater than binding by the RFC1 folate
carrier. Moreover, in the case of folic acid itself, binding to
RFC1 is approximately 2 orders of magnitude less than for
substituted reduced folates or folate analogs,3 which have
influx Km or Ki values in the low micromolar range. For all
other transporters described,1-4 the affinity for all these
folate compounds is similar and in the low micromolar
range. Thus the relative inability of folic acid to inhibit
internalization of competing, structurally similar permeants
in tumor cells is a defining characteristic of RFC1-mediated
transport. We have taken advantage of these differences to
delineate FRA- versus RFC1- mediated internalization of 3H
methotrexate in these mesothelioma cell lines.
The physiologic or pharmacologic significance of FRA
gene expression in mesothelioma is not understood nor is it
understood in ovarian carcinoma, the only example of high-
level expression in patient-derived material.22 Despite this
high level of expression of FRA in ovarian cancer cells,
Figure 3. Real-time RT-PCR determinations of FRA and RFC1 gene expression in the VAMT-1 human mesothelioma
cell line. Rn represents the normalized fluorescence signal minus the baseline signal established in the first few
cycles of PCR. CT represents the fractional cycle number at which an increase in the reporter fluorescence above
a set threshold (horizontal black line) is first detected. -Actin gene expression was used as a control to normalize
these PCR reactions. These data are representative of replicate runs. Additional details are given in the text.
Figure 4. Relative levels of RFC1 and FRA mRNA expression in various cell lines. The y axis scale is in relative units
(specific target mRNA relative to -actin mRNA expression).
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earlier studies from our laboratory16 and, more recently,
elsewhere,23 as well as our studies described here, have
documented internalization of folate compounds exclu-
sively as a carrier-mediated process in these cells in culture,
as well as for patient-derived ovarian cancer cells. Our
findings showed that internalization of 3H methotrexate in
the 4 mesothelioma cell lines examined was also predomi-
nantly RFC1 mediated. Because of the relative inefficiency
of receptor-mediated versus RFC1-mediated internaliza-
tion,1-6 the low to modest level of expression of this receptor
observed here in mesothelioma cells has no effect on total
intracellular accumulation of this folate analog, as shown by
the actual measurements of 3H methotrexate influx. The
situation with regard to gene expression was similar in those
mesothelioma cells derived directly from patients. Thus, the
lack of a role for FRA in the mediated internalization of
folate analogs in human mesothelioma cells relates to the
fact that both gene expression and transport efficiency of
FRA is considerably less than that of RFC1 in this neo-
plasm.
The documentation of overexpression of the FRA gene in
mesothelioma compared with in normal adjacent tissue is
not sufficient to conclude that FRA has a role in making this
tumor susceptible to antifolates. The previous study14 mak-
ing this observation failed to look at the corresponding
RFC1 level of expression. Our studies, on the other hand,
compared the level of expression of both genes and also
carried out transport experiments in mesothelioma cell
lines, clearly showing primarily carrier-mediated internal-
ization of 3H methotrexate. This information is of impor-
tance if RFC1 gene expression is to be used as a molecular
marker for clinical response to folate analogs in this human
neoplasm and as a focus for new efforts at designing more
efficacious analogs. Prospective studies focusing on the
former question will need to be carried out in the context of
clinical trials of newer folate analogs to establish the rele-
vance of RFC1 gene expression. Such a trial examining the
efficacy of a new 10-deazaaminopterin analog (10-propar-
gyl-10-deazaaminopterin) is currently in progress.24
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